A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a phase I/II, open-label, non-randomized, multicentre study to evaluate the clinical
activity of vactosertib plus imatinib in desmoid tumor. Based on the background, TGF-β
inhibition as a potential therapeutic target for desmoid tumor and convey significant
implications for the clinical development. Therefore, investigator will conduct the phase II
trial of vactosertib in combined with imatinib in desmoid tumor.